bisnafide profile

Bisnafide is a synthetic small molecule that inhibits the activity of the enzyme mitochondrial complex I. This inhibition leads to the generation of reactive oxygen species (ROS), which are believed to play a role in the anti-cancer activity of bisnafide. Research indicates that bisnafide has anti-cancer properties, particularly against leukemia and lymphoma cells, and exhibits potential for use in treating other cancers. The molecule is studied for its potential therapeutic applications in cancer treatment. The mechanism of action involves inducing apoptosis (programmed cell death) in cancer cells, which leads to their elimination. Bisnafide's mechanism of action is linked to its ability to disrupt mitochondrial function and induce oxidative stress. It is being investigated as a potential treatment for various cancers, including acute myeloid leukemia and lymphoma. Bisnafide's synthetic route involves multiple steps and starts from readily available starting materials. The compound is chemically characterized by its distinct molecular structure, which contributes to its biological activity.'

bisnafide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	60917
CHEMBL ID	1178861
SCHEMBL ID	9136683
MeSH ID	M0225499

Synonym
bisnafide
5-nitro-2-[(2r)-1-[2-[[(2r)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione
CHEMBL1178861
62h4w26906 ,
bisnafide [inn]
unii-62h4w26906
1h-benz(de)isoquinoline-1,3(2h)-dione, 2,2'-(1,2-ethanediylbis(imino((1r)-1-methyl-2,1-ethanediyl)))bis(5-nitro-
1h-benz(de)isoquinoline-1,3(2h)-dione, 2,2'-(1,2-ethanediylbis(imino(1-methyl-2,1-ethanediyl)))bis(5-nitro-, (r-(r,r))-
n,n'-(ethylenebis(imino((r)-1-methylethylene)))bis(3-nitronaphthalimide)
bisnafide [who-dd]
SCHEMBL9136683
Q27263482
2,2'-((2r,2'r)-(ethane-1,2-diylbis(azanediyl))bis(propane-1,2-diyl))bis(5-nitro-1h-benzo[de]isoquinoline-1,3(2h)-dione)
AKOS040746629

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	15 (93.75)	18.2507
2000's	1 (6.25)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (11.76%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	15 (88.24%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	2.41	2	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cytosine [no description available]	2.01	1	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
spermidine [no description available]	2	1	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
thymine [no description available]	2.01	1	pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite
amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.	1.98	1	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	1.98	1	dihydroxyanthraquinone	analgesic; antineoplastic agent
thymidine [no description available]	1.98	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
uridine [no description available]	1.98	1	uridines	drug metabolite; fundamental metabolite; human metabolite
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	1.98	1	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
1-naphthylamine 1-Naphthylamine: A suspected industrial carcinogen (and listed as such by OSHA). Its N-hydroxy metabolite is strongly carcinogenic and mutagenic.. naphthylamine : A primary arylamine that is naphthalene substituted by an amino group at unspecified position.. 1-naphthylamine : A naphthylamine that is naphthalene substituted by an amino group at position 1.	2	1	naphthylamine	human xenobiotic metabolite
amonafide xanafide: salt formulation of amonafide; DNA-intercalating agent and topoisomerase II inhibitor	1.99	1	isoquinolines
naphthalimides Naphthalimides: Compounds with three fused rings that appear like a naphthalene fused to piperidone or like a benz(de)isoquinoline-1,3-dione (not to be confused with BENZYLISOQUINOLINES which have a methyl separating the naphthyl from the benzyl rings). Members are CYTOTOXINS.	2.4	2
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	1.99	1	divalent inorganic anion; phosphite ion
mitonafide [no description available]	2	1
arabinose [no description available]	1.98	1	L-arabinose	Escherichia coli metabolite; mouse metabolite
elinafide elinafide: structure given in first source	2.01	1
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	1.98	1	actinomycin	mutagen
guanine [no description available]	2.01	1	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite

Condition	Relationship Strength	Studies	Trials
Cancer of Colon [description not available]	2.67	3	0
Leukemia L 1210 [description not available]	2.39	2	0
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	2.39	2	0
Malignant Melanoma [description not available]	1.98	1	0
B16 Melanoma [description not available]	1.98	1	0
Experimental Mammary Neoplasms [description not available]	1.98	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.67	3	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	1.98	1	0
Breast Cancer [description not available]	1.98	1	0
Cancer of Lung [description not available]	1.98	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	1.98	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	1.98	1	0
Adenocarcinoma, Basal Cell [description not available]	2.39	2	0
Benign Neoplasms [description not available]	4.07	3	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.39	2	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	4.07	3	1
Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)	1.98	1	0
Animal Mammary Carcinoma [description not available]	1.98	1	0
Thrombopenia [description not available]	3.38	1	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	3.38	1	1

bisnafide

Description

Cross-References

Synonyms (14)

Research Excerpts

Research

Studies (16)

Market Indicators

Research Demand Index: 11.16

Study Types